Table 6 Overview of included studies – base case (sensitivity analyses) presented
Kulasingam 2003 [27] | Sanders 2003 [28] | Goldie 2004 [29] | Taira 2004 [32] | Kulasingam 2007 [39] | |
Country | US | US | US | US | Australia |
Modelling approach | Markov Model | Markov Model | Markov Model | Deterministic transmission Model | Markov Model |
Disease included | HPV, CIN1,2–3, CC | HPV,SIL, CC | HPV, CIN1,2–3, CC | HPV | HPV, CIN1,2–3, CC |
HPV types (High Risk/ Low Risk) | yes/yes | 16,18,31,33,35,39,45,51,52,56,58,59,68/20,22 | 16,18,non 16–18/yes | 16,18/- | 16,18,non 16–18/yes |
Target population | 12 F to 85 F | 12 F | 13 F to ≈ 17 F | 12 F to 50 F | 12 F to 85 F |
Time horizon | 12 to 85 | 12 to Lifetime | 12 to Lifetime | 12 to Lifetime | 12 to 85 |
Discount rates | 3% | 3% (0–5%) | 3% | 2% (0–5%) | 5% (3–5%) |
Perspective | Societal | Societal | Societal | Societal | Societal |
Goldhaber-Fiebert 2008 [33] | Kim 2008 [31] | Coupe, de Melker 2009 [35] | Coupe, van Ginkel 2009 [36] | Kim 2009 [30] | |
Country | US | US | Netherlands | Netherlands | US |
Modelling approach | Individual-based model | Dynamic Model | Markov Model | Markov Model | Hybrid model (transmission model + disease model) |
Disease included | HPV, CIN1,2–3, CC | CIN, CC, other HPV-related disease | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | CIN, CC, other HPV-related diseases |
HPV type (High Risk/Low Risk) | 16,18,non 16–18/yes | 16,18/- | 16,18,31,33,35,39,45,51,52,56,58,59,68/- | 16,18,31,33,35,39,45,51,52,56, 58,59,66,68/- | 16,18/- |
Target population | 9 F to Lifetime | 12 F | 12 F | 12 F | 12 F + M |
Time horizon | 9 to Lifetime | 12 to Lifetime | 12 to Lifetime | 12 to Lifetime | 12 to Lifetime |
Discount rates | 3% | 3% | 4% (Costs) 1.5% (Health) | 4% (Costs) 1.5% (Health) | 3% |
Perspective | Societal | Societal | Societal | Societal | Societal |
Kim, Ortendahl 2009 [34] | Accetta 2010 [38] | Diaz 2010 [43] | Demarteau 2011 [41] | Burger 2012 [42] | |
Country | US | Italy | Spain | France | Norway |
Modelling approach | Individual-based Model | Markov Model | Micro-simulation model | Markov Model | Simulation model |
Disease included | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC |
HPV type (High Risk/Low Risk) | 16,18/- | 16,18,non 16–18/yes | 16,18,non 16–18/yes | - | 16,18,non 16–18/yes |
Target population | 35–45 F | F | 11–14 F | 12 F | F |
Time horizon | 35–45 to Lifetime | 11 to Lifetime | 11 to lifetime | 12 to lifetime | Lifetime |
Discount rates | 3% | 3% | 3% | 3% (Costs) 1.5% (Health) (0–5%) | 4% |
Perspective | Societal | Societal | Societal | Societal | Societal |
Coupe 2012 [37] | Tully 2012 [40] | Berkhof 2013 [44] | |||
Country | Netherlands | Canada | Slovenia, Poland | ||
Modelling approach | Individual-based model | Transmission model | Individual-based model | ||
Disease included | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | HPV, CIN1,2–3, CC | ||
HPV type (High Risk/Low Risk) | 16,18,31,33,35,39,45,51,52,56, 58,59,66,68/- | 16,18,non 16–18/- | 16,18,−/− | ||
Target population | 10 F | 18 F | 12 F | ||
Time horizon | 10 to Lifetime | 80 years | Not clear | ||
Discount rates | 4% (Costs) 1.5% (Health) (No-3%) | 3% | 3% | ||
Perspective* | Societal | Societal | Societal | ||